Breaking Finance News

BidaskClub upgraded Calithera Biosciences Inc (NASDAQ:CALA) to Buy in a statement released earlier today.

Having a price of $17.90, Calithera Biosciences Inc (NASDAQ:CALA) traded 15.35% higher on the day. With the last close up 9.14% from the two hundred day average, compared to the Standard & Poor's 500 Index which has increased 0.05% over the same time period. CALA has recorded a 50-day moving average of $15.88 and a 200-day moving average of $12.74. 1,034,907 shares of the stock were exchanged, up from an average trading volume of 843,980

BidaskClub has upgraded Calithera Biosciences Inc (NASDAQ:CALA) to Buy in a report released on 7/07/2017.

See Chart Below

Calithera Biosciences Inc (NASDAQ:CALA)

With a market cap of $0, Calithera Biosciences Inc has 52 week low of $2.20 and a 52 week high of $20.05 .

Also covering Calithera Biosciences Inc's target, a total of 2 analysts have released a research note on CALA. The one year target is $12.50 with zero equity analysts rating the company a strong buy, zero brokerages rating the company a buy, zero analysts rating the company a hold, zero brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

About Calithera Biosciences Inc (NASDAQ:CALA)

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.